Valuation
- Market cap
- 3,178,751,000
- Revenue TTM
- $376,070,000
- Net income TTM
- $-16,140,000
- PE ratio
- 125.86
- Forward PE
- 62.93
- Profit margin
- -4.29%
- Debt to equity
- 0.49
Trading
- Volume
- 1,778,400
- Avg volume
- 2,413,204
- Day's range
- $25.01 – $25.78
- Shares out
- 125,692,000
- Stochastic %K
- 5%
- Beta
- 1.57
- Analysts
- Strong Sell
- Price target
- $37.00
Company profile
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selec...
Show more
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 805 418 5006
- Website
- https://www.arcutis.com
- Address
- 3027 Townsgate Road, Suite 300, Westlake Village, United States
Latest news
No headlines yet.
